



Published in final edited form as:

*Proteins*. 2003 November 1; 53(2): 229–240. doi:10.1002/prot.10428.

## Molecular Dynamics Simulations of Galectin-1-oligosaccharide Complexes Reveal the Molecular Basis for Ligand Diversity

Michael G. Ford<sup>1</sup>, Thomas Weimar<sup>2</sup>, Thies Köhli<sup>2</sup>, and Robert J. Woods<sup>1,\*</sup>

<sup>1</sup>Complex Carbohydrate Research Center, University of Georgia, 220 Riverbend Road, Athens, Georgia 30602

<sup>2</sup>Institute for Chemistry, Medical University of Lübeck, Ratzeburger Allee 160, D-23538 Lübeck, Germany

### Abstract

Galectin-1 is a member of a protein family historically characterized by its ability to bind carbohydrates containing a terminal galactosyl residue. Galectin-1 is found in a variety of mammalian tissues as a homodimer of 14.5-kDa subunits. A number of developmental and regulatory processes have been attributed to the ability of galectin-1 to bind a variety of oligosaccharides containing the Gal- $\beta$ -(1,4)-GlcNAc (LacNAc<sub>II</sub>) sequence. To probe the origin of this permissive binding, solvated molecular dynamics (MD) simulations of several representative galectin-1-ligand complexes have been performed. Simulations of structurally defined complexes have validated the computational approach and expanded upon data obtained from X-ray crystallography and surface plasmon resonance measurements. The MD results indicate that a set of anchoring interactions between the galectin-1 carbohydrate recognition domain (CRD) and the LacNAc core are maintained for a diverse set of ligands and that substituents at the nonreducing terminus of the oligosaccharide extend into the remainder of a characteristic surface groove. The anionic nature of ligands exhibiting relatively high affinities for galectin-1 implicates electrostatic interactions in ligand selectivity, which is confirmed by a generalized Born analysis of the complexes. The results suggest that the search for a single endogenous ligand or function for this lectin may be inappropriate and instead support a more general role for galectin-1, in which the lectin is able to crosslink heterogeneous oligosaccharides displayed on a variety of cell surfaces. Such binding promiscuity provides an explanation for the variety of adhesion phenomena mediated by galectin-1.

### Keywords

AMBER; galectin; GBSA; GLYCAM; molecular dynamics

## INTRODUCTION

Galectin-1 is one of a family of 11  $\beta$ -galactoside binding vertebrate lectins.<sup>1</sup> As an S-type lectin, it contains free sulfhydryl groups that must be maintained in a reduced state for full binding activity, but does not require the presence of  $\text{Ca}^{2+}$  for activity. Galectin-1, expressed as a homodimer of 14.5-kDa subunits, is found in a wide range of tissue types and has been shown to play a part in the regulation of cellular growth and differentiation<sup>2</sup> as well as the immune response.<sup>3</sup>

Glycoproteins, such as laminin,<sup>4</sup> fibronectin,<sup>5</sup>  $\text{CD}_{45}$ <sup>6</sup> LAMP I and II,  $\alpha_7\beta_1$  integrin,<sup>7</sup> and the glycolipid  $\text{G}_{\text{M1}}^8$  have been proposed as in vivo ligands for galectin-1. Gal- $\beta$ -(1,4)-GlcNAc (LacNAc<sub>II</sub>) (1) disaccharide units are found in each of the *N*-, *O*-, and ceramide-linked glycans found in these molecules. The various in vitro effects exhibited by this lectin have been attributed to the ability of dimeric galectin-1 to crosslink these oligosaccharides.<sup>9,10</sup> A number of crystal structures of galectins with bound oligosaccharide ligands have been determined,<sup>10–14</sup> including the structure of bovine galectin-1 with LacNAc<sub>II</sub> from Liao et al.<sup>15</sup> The ligands in each of the reported structures have a  $\beta$ -linked galactosyl residue at the nonreducing terminus. The carbohydrate recognition domain (CRD) consists of a deep channel, formed by an antiparallel  $\beta$ -sandwich, which spans the entire length of the monomeric subunit. The structure of galectin-1 with LacNAc bound in the CRD highlights several important protein-carbohydrate interactions. The interactions between Arg-48 and His-44, with the 4-hydroxyl group of the galactosyl residue provide the binding specificity for galactose, are conserved throughout the entire galectin family.<sup>16,17</sup>

Galectin-1 can be considered to contain a CRD that is characteristic for the galectin family. The  $\beta$ -sheet motif, which comprises the galectin-1 CRD, shares a high level of structural homology with other galectins,<sup>18</sup> especially with galectin-2 and galectin-3. Structural homology with the galectin-1 CRD extends not only to the CRDs of other galectin family members, but also to mammalian pentraxins, such as serum amyloid protein and legume lectins. This homology highlights the conservation of this structural motif throughout a number of different lectins.

The energetics of the binding of Gal-terminating and non-Gal-terminating ligands with galectin-1 have been well characterized.<sup>19–22</sup> However, the mechanism by which galectin-1 accommodates non-Gal-terminating ligands as well as those containing multiple LacNAc units remains undetermined. Early results from ELISA experiments by Zhou and Cummings<sup>23</sup> on polygalactosamines from CHO cells, suggested that up to four LacNAc units could be accommodated by the galectin-1 CRD and that these longer ligands did not require a terminal galactosyl residue for binding. In addition, it has been proposed that galectin-1 binds to the Type II polygalactosamine chains found on laminin or fibronectin through interactions with the LacNAc repeat unit.<sup>24</sup> No X-ray structural data have been reported for complexes between galectin-1 and any non-Gal-terminating ligands.

We have performed solvated MD simulations on a number of biologically relevant galectin-1-ligand complexes using the AMBER force field, augmented with the GLYCAM<sup>25</sup> parameters for carbohydrates. Explicitly solvated MD simulations have been

shown to reproduce the experimental structures of lectin-carbohydrate<sup>26,27</sup> and antibody-carbohydrate<sup>28,29</sup> complexes. Nevertheless, to establish the accuracy of the theoretical methods in the case of galectin-1, preliminary simulations were performed on the X-ray structure of the galectin-1-LacNAc complex.<sup>15</sup> The simulations were then extended to novel, but related, galectin-1-ligand complexes. To ensure that the calculations were able to reproduce the specificity of galectin-1 binding, we have included simulations of two complexes involving ligands, which show no measurable binding affinity *in vitro*.<sup>19</sup> The inclusion of negative controls in MD simulations is rare, but here is found to be a useful technique to assess the sensitivity of the simulation to changes in ligand structure.

From the MD data, it is possible to analyze the contributions from key structural properties, such as the hydrogen bonding and van der Waals and electrostatic forces, as well to determine the presence of additional contacts made by the larger ligands. Analysis of snapshots taken from the molecular trajectories allow for estimates of the energetic components responsible for ligand binding. This analysis facilitated the development of a model for the mechanism of galectin-1-ligand binding, which explains both the diversity and relative affinities of the carbohydrate ligands.

## MATERIALS AND METHODS

### Molecular Modeling and Dynamics

Coordinates for the galectin-1-LacNAc complex<sup>15</sup> were retrieved from the Protein Data Bank<sup>30</sup> (pdb: 1slt). A single monomer of the dimeric complex was used in the simulations. Hydrogen atoms were added to the X-ray coordinates, and the system was solvated with the EDIT module of AMBER. All histidine residues were assumed to be neutral and were protonated at the N $\epsilon$  position. For the water droplet, a sphere of TIP3P waters<sup>31</sup> with a radius of 26 Å was centered at the ligand center of mass. Diffusion of waters out of this droplet was prevented through the use of a half-harmonic potential applied at the droplet surface. For periodic boundary condition (PBC) simulations, the protein-ligand complex was placed within a theoretical box of TIP3P water with approximate dimensions of 45 × 55 × 60 Å. In all cases the CRD was defined with a residue-based cutoff, consisted of all amino acids containing any atom within 12 Å of any atom in LacNAc<sub>II</sub>, and was allowed complete motional freedom. This 39-residue subset included most of the front  $\beta$ -sheet and the loops that interact with the ligand (residues 27–32, 40–72, 107, and 110). The remainder of the protein was either restrained in its experimentally determined position or allowed motional freedom, as described in the text. The simulations were performed with the all-atom AMBER force field<sup>32</sup> using the PARM94 parameters for proteins,<sup>33</sup> augmented with GLYCAM parameters<sup>25</sup> (version 99d) for oligosaccharides. Partial atomic charges for the ligands were computed from quantum mechanical molecular electrostatic potentials as reported.<sup>34</sup> The initial unfavorable contacts made by the solvent were removed by 1500 cycles of energy minimization; 10 cycles of steepest descent were followed by 1490 steps of conjugate gradient. The energy of the solvent molecules and binding site residues was then minimized further for 1500 steps. Energy minimization was followed by a 150-ps period of simulated annealing, during which the temperature was raised from 5 to 300 K over 50 ps, maintained at 300 K for 50 ps, and then cooled to 5 K over 50 ps. The energy of the whole

system was then minimized, followed by heating from 5 K to 300 K over 50 ps, with initial velocities assigned from a Maxwellian distribution at 5 K.

For the simulations utilizing the droplet and PBC solvation methods, an 8 Å cutoff was used for calculating nonbonded interactions. One to four electrostatics and nonbonded interactions were scaled by the default values of 1/1.2 and 1/2.0, respectively. Production dynamics were performed at 300 K using a 2-fs time-step, with the SHAKE algorithm applied to all hydrogen-containing bonds. For the Particle Mesh Ewald (PME) simulation,<sup>35</sup> a 1 Å grid spacing was used to calculate the electrostatic energies, with a fourth-order spline used for interpolation.

The energetic analysis of the galectin-1-ligand trajectories was undertaken using the MM-PBSA module of AMBER 7.<sup>36</sup> For the 2-ns trajectories, snapshots of the coordinates were taken every 10 ps. The resulting 200 snapshots were analyzed with the modified generalized Born solvation model, modified for use with PARM 94<sup>36</sup> to obtain the energetic contributions from solvation. Average molecular mechanical energies were also computed from the same set of 200 snapshots. The normal mode analysis<sup>32</sup> was performed on 10 snapshots, corresponding to 200-ps intervals. The energies of the structures used in the normal mode analysis were minimized to within a cutoff of  $10^{-4}$  kcal/(mol · Å). No distance cutoff was applied to nonbonded interactions. The resulting enthalpic and entropic terms were combined to give estimates of the binding free energies.

## Ligand Docking

The oligosaccharide ligands were docked in the binding site by superimposing the LacNAc component with the equivalent residues observed in the crystal structure of the galectin-1-LacNAc<sub>II</sub> complex.<sup>15</sup> Initial alignment of the remaining residues was achieved by evaluating the steric fit as a function of the glycosidic torsion angles. In the case of Neu5Ac- $\alpha$ -(2-3)-LacNAc, each of the three low energy rotamers for the  $\alpha$ -(2,3) linkage ( $\varphi = +60^\circ$ ,  $-60^\circ$  and  $180^\circ$  with  $\psi = 0^\circ$ ) was initially examined. Analysis of these three complexes showed that the  $-60^\circ$  structure made steric clashes with the protein and was eliminated from further study. Both the  $+60^\circ$  and  $180^\circ$  structures were able to fit and were subjected to preliminary MD refinement, during which the  $+60^\circ$  rotamer spontaneously interconverted to the  $180^\circ$  structure (data not shown). All subsequent studies were performed with the  $180^\circ$  Neu5Ac- $\alpha$ -(2-3)-LacNAc structure. LacNAc<sub>I</sub>, in which the  $\beta$ -(1,4) glycosidic linkage is replaced by a  $\beta$ -(1,3) linkage, was overlaid with the heavy atoms of the sugar rings of LacNAc<sub>II</sub>. This change in conformation resulted in a conformation in which the *N*-acetyl group was positioned  $180^\circ$  away from its position in the crystal structure. For (LacNAc)<sub>2</sub>, the disaccharide containing the reducing terminus was superimposed with the LacNAc disaccharide from the crystal structure. The glycosidic torsion angles associated with distal LacNAc were varied so as to minimize steric clashes with the protein. The resultant orientation ( $\varphi_{1-4} = 56.3^\circ$   $\psi_{1-4} = -4.6^\circ$   $\varphi_{1-3} = 41.1^\circ$   $\psi_{1-3} = -15.4^\circ$ ) was consistent with expectations based on the *exo*-anomeric effect.<sup>37</sup> Neu5Ac- $\alpha$ -(2,3)-LacNAc was neutralized with a Na<sup>+</sup> counterion placed 2.5 Å away from the carbon of the carboxylic acid, along the bisector of the O—C—O angle. 3'-OSO<sub>3</sub>-LacNAc was treated in a similar manner, with the counterion placed 2.5 Å away from the sulfur atom, along the trisector of the SO<sub>3</sub> angle.

## RESULTS

### Galectin-1 Affinity for Oligosaccharide Ligands

The relative binding affinities for galectin-1 with a number of carbohydrates that contain a LacNAc core are presented in Table I. The binding data in Table I clearly illustrate the remarkable ability of the galectin-1 CRD to bind a variety of glycans (see Scheme 1). The similar affinities of oligosaccharides containing LacNAc<sub>II</sub> (Gal- $\beta$ -(1,4)-GlcNAc) (1) and LacNAc<sub>I</sub> (Gal- $\beta$ -(1,3)-GlcNAc) (2) highlight the fact that the change in linkage has little effect on overall molecular shape, a fact that was first observed for disaccharide components of Lewis blood group antigens.<sup>40</sup> The affinities for anionic ligands implicate electrostatic interactions in ligand binding. The attachment of an anionic moiety at the 3'-position of LacNAc can considerably enhance ligand affinity (see Table I). One such oligosaccharide, Neu5Ac- $\alpha$ -(2,3)-LacNAc (4), is a potentially important biological ligand, because of its prevalence in mammalian *N*-linked glycans. Further, 3'-*O*-sulfation of LacNAc increases affinity sixfold relative to LacNAc. 3'-OSO<sub>3</sub>-LacNAc (3) has been shown to be an important component of glycolipids from brain, kidney, spleen, granulocytes, stomach, and intestine.<sup>41,42</sup> The lower affinity seen for the 6'-*O*-sulfated oligosaccharide relative to the 3'-*O* analog further suggests that the electrostatic interactions are specific. Elucidating the role of charge-charge interactions in stabilizing galectin-ligand complexes has therefore become critical to understanding the ligand affinities.

A crystal structure of the galectin-1-LacNAc complex served the basis for the MD simulations.<sup>15</sup> The X-ray structure showed the presence of several hydrogen bonds, which contribute to ligand affinity. Seven amino acid residues, which interact directly with the LacNAc functional groups, are highly conserved within the galectin family.<sup>16</sup> The hydrogen bonding network between hydroxyl groups of Gal and binding site residues His-44, Asn-46, and Trp-68 is responsible for galactose binding specificity. Glu-71 and Arg-48 make contacts with both sugars of the disaccharide, whereas His-52, Asp-54 and Arg-73 form contacts with the GlcNAc moiety. The relevant structural details of this complex are shown in Figure 1. Utilizing this crystal structure, oligosaccharides 2, 3, 4, and 5 were modeled into the galectin-1 binding site, as described in Material and Methods, and are shown in Figure 2.

### MD Simulation of Galectin-1-oligosaccharide Complexes

The stability and dynamics of proteins in MD simulations depends greatly on the treatment of solvation and electrostatic forces. In order to achieve a correct balance between intra- and intermolecular forces, we believe it is necessary to employ an explicit solvation model. To determine a computational protocol that could achieve a high degree of accuracy within a reasonable simulation timeframe, three different treatments of explicit solvation and long-range electrostatics were examined. Our initial approach was to surround the binding site with a droplet of water and define a subset of crucial binding-site residues. This protein subset, along with the ligand and surrounding water molecules, was allowed complete motional freedom, whereas the remainder of the protein was kept frozen in its crystallographic conformation. In these droplet simulations, the water was prevented from diffusing away from the complex by applying a restraint potential. Possible artifacts, arising from the use of a partially restrained water droplet, were addressed by a second simulation,

in which the protein-ligand complex was fully solvated within a box of TIP3P water molecules. These simulations used the same protein restraints and 8 Å nonbonded cutoff as in the droplet simulations, but were performed under periodic boundary conditions (PBC). The PBC treatment enabled the simulation to be performed at room temperature and pressure.

The third computational approach employed the use of a fully unrestrained PBC simulation using the Particle Mesh Ewald (PME)<sup>35</sup> method to treat long-range electrostatic forces. The PME method includes electrostatic effects that are omitted by the use of a cutoff in standard PBC simulations. The more complete treatment of interatomic forces, as computed using PME, allowed the removal of all restraints on the protein and therefore enabled an estimation of the influence of the restraints used in the droplet and PBC (non-PME) simulations. A comparison of the droplet solvation approach with both the PBC and PBC/PME methods indicated that the droplet simulation gave results comparable to both of the more sophisticated treatments, while taking approximately one-third the CPU time of the PBC simulation. An analysis of hydrogen-bond distances in the galectin-1-ligand complexes is shown in Table II.

## Hydrogen Bonding

The most notable feature of the data in Table II is the high level of agreement between the values of the interatomic distances seen in the crystal structure with those seen in all of the solvated MD simulations. Nearly all of the hydrogen bonding distances between LacNAc functional groups and the side chains of binding site residues are within 0.5 Å of the experimental distances, with small standard deviations. Specifically, the key interactions between Gal-O4 and His-44 N $\epsilon$ , Asn-46 O $\delta$ 1 and Arg-48 N $\eta$ 2 are noteworthy for their relatively short distances and low standard deviations, suggesting that they are very strong hydrogen bonds. The interactions of Gal-O6 (with Asn-61 N $\delta$ 2 and Glu-71 O $\epsilon$ 2) and GlcNAc-O3 (with Arg-48 N $\epsilon$ 1 and Glu71 O $\epsilon$ 1) also show values indicative of a relatively strong hydrogen bonding network.

The interatomic distances of hydrogen bonded atoms are the most commonly used structural measure of the strength of hydrogen bonds. Nonetheless, the standard deviations obtained from the MD data also help to rank the relative strengths. For example, the standard deviations observed for the interatomic distances between the Gal-O4 and both His-44 N $\epsilon$  and Arg-48 N $\eta$  are lower than those observed for the Gal-O6 interaction with the carboxylate oxygens of Glu-71, suggesting that the former are stronger hydrogen bonds. Nonetheless, the overall agreement with experiment was satisfactory and based on these preliminary studies, all subsequent simulations were performed with the droplet solvation model.

For all complexes with extended ligands (**3**, **4**, and **5**), the core LacNAc residues show an overall conservation of hydrogen bonding geometry (Table III). Interactions involving the Gal-O4 (with His-44 N $\epsilon$ , Asn-46 O $\delta$ 1, and Arg-48 N $\epsilon$ 2), Gal-O6 (with Asn-61 N $\delta$ 2 and Glu-71-O $\epsilon$ 2), and GlcNAc-O3 (with Arg-48 N $\eta$ 1 and Glu-71 O $\epsilon$ 1) were maintained for all of the ligands. Even in the case of **2**, which contains a Gal- $\beta$ -(1,3)-GlcNAc linkage, many of the LacNA-c<sub>II</sub>-core interactions were maintained, particularly those between Gal-O4 and

His-44 and between Gal-O6 and Asn-61. The loss of the contacts between galectin-1 and the GlcNAc in **2** is due to the change in linkage position, which results in a 180° rotation of the GlcNAc ring relative to its orientation in **1**. This conformation has previously been proposed from an analysis of the X-ray structure of galectin-1 bound to a complex biantennary oligosaccharide.<sup>10</sup> Notably, this conformational change appears to result in a slight decrease in the relative affinity of **2** (see Table I).

Hydrogen bonds between the extended portions of the non-Gal-terminating ligands and the CRD are presented in Table IV. For the complex with **4**, the interactions between His-52, and the carboxylic acid of Neu5Ac as well as those between Trp-68 and the glyceryl side chain of Neu5Ac are the primary interactions between the CRD and the sialic acid. In the terminal LacNAc unit of **5**, the strongest hydrogen bonds were observed between Asp38 and Gal<sub>2</sub>-O3, as well as between Asp38 and the amide proton of the *N*-acetyl group in GlcNAc<sub>2</sub>. The binding of **1** to the CRD, and the interactions between the extended portions of **4** and **5** are similar, in that the protein-carbohydrate interactions seen are confined to one face of each oligosaccharide. In addition, both interactions have at most only one or two strong hydrogen bonds between the CRD and extended sugars.

### Aromatic Ring Stacking

In addition to hydrogen bonding between the protein and oligosaccharide ligands, hydrophobic interactions between sugar rings and aromatic amino acid side chains in the CRDs of lectins and anticarbohydrate antibodies are commonly observed.<sup>18,43</sup> The geometries of the aromatic stacking interactions, between the conserved Trp-68 and the galactosyl ring in each complex, are presented in Table V. We have characterized this interaction by the angle ( $\theta$ ) between the normals to the planes defining the galactosyl ring and the six membered ring of tryptophan. For a perfectly parallel stacking arrangement  $\theta$  would have a value of 180°. In the simulations, each ligand formed a stacking interaction with Trp-68, with an overall average  $\theta$  value of 139°, which compares favorably with the X-ray value of 142°. Further characterization of these interactions may be obtained by measuring the distance *R* between the geometric centroids of the pyranosyl and aromatic rings. The average value of *R* for each ligand was 5.7 Å; slightly longer than that present in the X-ray structure (5.1 Å), presumably reflecting the influence of internal motions.

### Structural Analysis of Bound and free Galectin-1 Ligands

The average values for the glycosidic torsion angles of each ligand, for both the protein-bound and free states, are presented in Table VI. As is typical for oligosaccharide-protein complexes,<sup>44,45</sup> the glycosidic linkages of the free oligosaccharides exhibited greater ranges of motion than when bound to galectin-1. The  $\phi$  and  $\psi$  torsion angles of the  $\beta$ -(1,4) linkage of the LacNAc<sub>II</sub> core remained within 15° of the crystal values of 52° and 13°, respectively, for all ligand complexes. The solution and bound conformation of the LacNAc core showed little variation in  $\phi$ , adopting the conformation preferred on the basis of the exo-anomeric effect.<sup>37</sup> The  $\psi$  angle, however, consistently displayed a modest distortion from the crystal structure geometry of approximately 15°. The large standard deviations seen in the  $\beta$ -(1,3) linkage of **5** reflect a highly flexible linkage, consistent with predictions based on gas-phase energy calculations for this linkage.<sup>46</sup>

## Negative Controls

In order to determine the extent to which the simulations were able to discriminate between high and very low affinity ligands,<sup>19</sup> galectin-1 complexes with a monosaccharide, GlcNAc (**6**) and the 4'-epimer of LacNAc, Glc- $\beta$ -(1,4)-GlcNAc or *N*-acetylmaltosamine (**7**) were examined. Over the course of the simulations, both negative controls diffused out of the binding site within 1500 ps, reaching positional RMSD values of 9 Å relative to their initial positions, in 680 and 1403 ps, respectively [Fig. 3(a)]. The diffusion may be characterized in terms of the specific sequence of hydrogen bond breakage, and in the case of **7**, began with the disruption of hydrogen bonds between GlcNAc-O3 and both Glu-71-O $\epsilon$ 2 and Arg73-N $\eta$ 2, at ~680 ps. This was followed by the loss of three hydrogen bonds between Arg-48 and ligand atoms GlcNAc-O3, GlcNAc-O4, and Glc-O5 between 1075 and 1112 ps. Hydrogen bonding pairs His-44 N $\epsilon$ -Glc-O4 and Asn-61 N $\delta$ 2-Glc-O6 persisted until 1348 and 1457 ps, respectively [see Fig. 3(b)]. In contrast to the case of the disaccharide, **6** alone did not show any persistent hydrogen bonds prior to diffusing out of the CRD.

## Electrostatic Interactions in Galectin-1 Complexes

Electrostatic potential mapping of the galectin-1 surface shows a large positively charged region at the entrance to the binding channel, shown in Figure 4. This observation, suggests the manner in which electrostatic complementarity plays a role in the binding of the anionic carbohydrates. The positive electrostatic potential observed in the galectin-1 CRD arises from several positively charged residues (Lys-28, Lys-63, Arg-48, and Arg-73) located within the CRD. Both Arg-48 and Arg-73 make direct contacts with the LacNAc<sub>II</sub> core, whereas Lys-28 and Lys-63 are located in the binding site near the 3'-OSO<sub>3</sub>-moiety in **3**.

## Binding Free Energy Estimates from MD Trajectories

Employing the trajectories from each of the droplet simulations, it was possible to compute estimates of the free energies of binding for each complex. This was performed in three stages. First, the water molecules were removed from the trajectories and the molecular mechanical energies computed for the complex, the unliganded receptor and for each ligand. These calculations were performed for each snapshot while maintaining the molecules in their bound conformations. Next, estimates of the solvation free energies were made for each component using a generalized Born solvation model optimized for use with AMBER, and consistent with our choice of partial atomic charges in the carbohydrate ligands.<sup>36</sup> Lastly, estimates of the entropy changes during complex formation were generated from a normal mode analysis of the energy-minimized structures. Recently, this combined protocol has been used successfully to examine the stabilities of antibody-hapten complexes,<sup>47</sup> as well as to estimate the relative stabilities of oligonucleotides,<sup>48</sup> and oligonucleotide complexes.<sup>49,50</sup> The accuracy of this approach is enhanced when there is negligible difference between the bound and free conformations for the ligand, as is the case in general here. The overestimation of the absolute binding free energies is due primarily to the use of a vacuum dielectric constant when computing the interior electrostatic interactions ( $\epsilon_{\text{int}} = 1$ ). In calculations employing non-polarizable force fields, or in cases where the protein is not given complete conformational freedom, larger interior dielectric values have been shown to perform well.<sup>51</sup> Further, it should be recalled that the simulations employ the monomer



subunit, whereas the experimental data are for binding to the dimer. Presented in Table VII are component energies for each ligand computed with  $\epsilon_{\text{int}} = 1$ , as well as total binding energies computed with  $\epsilon_{\text{int}} = 4$ .<sup>52</sup>

Several features are evident from the energetic analysis. The binding free energies correctly rank the affinities of the ligands, with the exception that ligand **4** is predicted to bind more weakly to galectin-1 than **1**. There are however, significant standard deviations on all of the binding free energies. Nevertheless, **3** is clearly predicted to bind better to galectin-1 than **1**, whereas **2** is correctly predicted to be the poorest ligand. It is impossible to discriminate between ligands **1**, **3**, and **4** on the basis of net molecular mechanical energies  $\langle E_{\text{MM}} \rangle$  alone, with values being indistinguishable within error limits. Instead, distinguishing the relative affinities of these ligands also requires the consideration of estimated solvation free energies  $\langle G_{\text{solv}} \rangle$  and entropic contributions  $\langle T S \rangle$ . For example, the enhanced affinity of the sulfated ligand does not arise only from direct electrostatic interactions  $\langle E_{\text{elec}} \rangle$  with the receptor. A complete picture of the overall electrostatic contribution  $\langle G_{\text{elec,tot}} \rangle$  requires that the interaction energies associated with solvation  $\langle G_{\text{solv}} \rangle$  be included. Both LacNAc ligands (**1** and **2**), display essentially identical favorable net van der Waals interactions  $\langle E_{\text{vdw}} \rangle$  and net entropic penalties  $\langle -T S \rangle$ . The weaker interaction with **2** appears to arise primarily from poor intermolecular and solvation electrostatic energies  $\langle G_{\text{elec,tot}} \rangle$ .

The much higher affinity predicted for **5** is the result of an interplay of electrostatics, in which a much more favorable intermolecular electrostatic term  $\langle E_{\text{elec}} \rangle$  over-comes a less favorable contribution from the polar component of solvation energy  $\langle G_{\text{pol}} \rangle$ . The predicted increase in affinity with increasing level of LacNAc polymerization is consistent with previous observations of galectin-1 binding, which suggested that an increase in poly-lactosamine chain length, leads to an increase in binding affinity.<sup>24</sup> In addition, recent measurements of galectin-1 affinities<sup>53</sup> show a threefold increase in binding affinity for Gal- $\beta$ -(1,4)-GlcNAc- $\beta$ -(1,3)-Gal- $\beta$ -(1,4)-Glc, relative to lactose.

## DISCUSSION

The tests of simulation protocols indicated that a relatively simple model, consisting of a partially restrained protein, a dynamic ligand and binding site with droplet solvation, performed as well as the more sophisticated PBC and PBC/PME simulations. The savings in computational time afforded by the use of the droplet model allowed the simulation of a number of biologically relevant galectin-1 complexes. These substituted lactosamines maintained a set of key LacNAc-CRD interactions, indicating that the differences in affinities observed for these ligands arise from the chemical properties of the substituents themselves and not from induced changes in the protein. Hydrogen bonds are also observed for the extended portions of the substituted lactosamines (**4** and **5**), between hydroxyl groups on one face of the oligosaccharide and the binding groove of the CRD. The relative weakness of these interactions indicates that factors other than hydrogen bonds must contribute to the range of observed affinities.

Coulombic interactions between the positive electrostatic potential of the galectin-1 CRD and anionic ligands serve to modulate their affinities. In the case of **3**, the sixfold increase in affinity can be ascribed to charge complementarity. 6'-O-sulfation leads to very little change in affinity, relative to LacNAc, presumably because favorable electrostatics are offset by the disruption of interaction between the Gal-O6 and galectin-1 CRD. The electrostatic complementarity between galectin-1 and **3** exists in the absence of any direct salt bridges between the sulfate group and amino acid residues within the CRD. This stands in contrast to the case of sulfate binding protein, in which the binding of HOSO<sub>3</sub> occurs via an extensive hydrogen bonding network.<sup>54</sup> The fact that the affinities of **1** and **4** are nearly equal, results from entropic penalties in the larger oligosaccharide, off-setting the favorable electrostatic interactions between the carboxylate of Neu5Ac and the positive electrostatic potential of the galectin-1 CRD (Table VII).

The analysis of the electrostatic properties of the solvated protein-ligand complexes gives another important clue to the factors responsible for carbohydrate binding by galectin-1. For ligands **1**, **3**, and **4**, differences in binding affinities are markedly dependent on solvation effects, as calculated from the generalized Born implicit solvation model. Details of the water structure as well as the role of water in mediating the binding affinities in these complexes are the subject of ongoing study.

Analysis of the structure of the oligosaccharide ligands of galectin-1, both in the protein-bound and free states shows an expected difference in the structure and flexibility of the glycosidic linkages. Although the free ligands, on the whole, exhibit greater flexibility about the glycosidic bonds, the average angles are in good agreement with the lowest energy conformations of disaccharide fragments.<sup>55</sup> This indicates that these ligands are bound in low energy conformations, with the largest effect being a decrease in the deviations from these averages. The normal mode analyses show that each ligand pays an entropic penalty upon binding, which is roughly proportional to the number of atoms in the ligand.

It should be remembered that, *in vivo*, these ligands do not occur as free oligosaccharides. The reducing termini of **1**, **3**, and **4** would be linked to larger glycans, whereas **5** would be incorporated within polylactosamine. These structural differences may have an effect on the conformational behavior of these oligosaccharides, which may influence their *in vivo* affinities. Further, affinities *in vivo* may result from avidity effects in longer oligosaccharides, such as (LacNAc)<sub>4</sub>.<sup>23</sup>

## CONCLUSIONS

The overall picture that emerges from these data is one in which a set of key LacNAc-CRD hydrogen bonding and ring stacking interactions tolerate a number of substitutions at the nonreducing terminus as well as differences in internal glycosidic linkages (**1** and **2**). The idea that galectin-1 is specific for Gal-terminating oligosaccharides is slightly inaccurate, and instead the protein can be thought to bind galactose in the context of lactose and lactosamine units occurring in a variety of positions in an oligosaccharide. The simulations of **4** and **5**, bound in the galectin-1 CRD, show that the binding groove of the protein can accommodate much longer oligosaccharide chains, without requiring significant

conformational changes in the CRD. Because of the highly polar nature of the ligands, the binding free energies depend on the balance between electrostatic interactions in the complex and in solution. This is a challenge for any implicit solvation model; however, the generalized Born approach used here was able to qualitatively rank the ligands, in agreement with the experimental data. A more detailed study of the effects of implicit solvation model on computed binding free energies for carbohydrate-protein interactions is currently underway.

The differences in affinities exhibited by galectin-1 ligands implicate differential carbohydrate modification as a factor in galectin-1 function. The promotion or inhibition of cell growth and metastasis, for example, is likely the result of the interaction of galectin-1 with differentially expressed cell-surface carbohydrates. Although crosslinking between heterotypic glycoprotein ligands has been proposed earlier,<sup>9,10</sup> we have provided a detailed structural mechanism, by which galectin-1 can accommodate a variety of ligands in the same CRD.

## Acknowledgments

In addition, the authors MGF and RJW would like to acknowledge James Prestegard and Jarrod Barnes for fruitful discussions.

Grant sponsor: National Institutes of Health; Grant number: NIGMS 55230. Grant sponsor: NATO.

## Abbreviations

<b>AMBER</b>	Assisted Model Building and Energy Refinement
<b>CHO</b>	chinese hamster ovary
<b>CD</b>	cluster of differentiation
<b>CRD</b>	carbohydrate recognition domain
<b>MD</b>	molecular dynamics
<b>PBC</b>	periodic boundary conditions
<b>GLYCAM</b>	Glycosides and Glycoproteins with AMBER
<b>LacNAc</b>	<i>N</i> -acetyllactosamine (Gal- $\beta$ -GlcNAc)
<b>LAMP</b>	lysosome associated membrane protein


## References

1. Cooper D, Barondes S. God must love galectins; He made so many of them. *Glycobiol.* 1999; 9:979–984.
2. Leffler H. Introduction to galectins. *Trends Glycosci Glycotech.* 1997; 9:9–19.
3. Rabinovich G, Baum L, Tinari N, Paganelli R, Natoli C, Liu F, Iacobelli S. Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response? *Trends Immunol.* 2002; 23:313–320. [PubMed: 12072371]
4. Zhou Q, Cummings RD. The S-type lectin from calf heart tissue binds selectively to the carbohydrate chains of laminin. *Arch Biochem Biophys.* 1990; 281:27–35. [PubMed: 1696449]


5. Andre S, Kojima S, Yamazaki N, Fink C, Kaltner H, Kayser K, Gabius HJ. Galectins-1 and -3 and their ligands in tumor biology. Non-uniform properties in cell-surface presentation and modulation of adhesion to matrix glycoproteins for various tumor cell lines, in biodistribution of free and liposome-bound galectins and in their expression by breast and colorectal carcinomas with/ without metastatic propensity. *J Cancer Res Clin Oncol*. 1999; 125:461–474. [PubMed: 10480338]
6. Walzel H, Schulz U, Neels P, Brock J. Galectin-1, a natural ligand for the receptor-type protein tyrosine phosphatase CD45. *Immunol Lett*. 1999; 67:193–202. [PubMed: 10369126]
7. Gu M, Wang W, Song W, Cooper D, Kaufman S. Selective modulation of the interaction of  $\alpha 7\beta 1$  integrin with fibronectin and laminin by L-14 lectin during skeletal muscle differentiation. *J Cell Sci*. 1994; 107:175–181. [PubMed: 8175907]
8. Kopitz J, von Reitzenstein C, Burchert M, Cantz M, Gabius H. Galectin-1 is a major receptor for ganglioside GM<sub>1</sub>, a product of the growth-controlling activity of a cell surface ganglioside sialidase, on human neuroblastoma cells in culture. *J Biol Chem*. 1998; 273:11205–11211. [PubMed: 9556610]
9. Symons A, Cooper D, Barclay AN. Characterization of the interaction between galectin-1 and lymphocyte glycoproteins CD45 and Thy-1. *Glycobiology*. 2000; 10:559–563. [PubMed: 10814697]
10. Bourne Y, Bolgiano B, Liao D, Strecker G, Cantau P, Herzberg O, Feizi T, Cambillau C. Crosslinking of mammalian lectin (Galectin-1) by complex biantennary saccharides. *Nat Struct Biol*. 1994; 1:863–870. [PubMed: 7773775]
11. Seetharaman J, Kanigsberg A, Slaaby R, Leffler H, Barondes S, Rini JM. X-ray crystal structure of the human galectin-3 carbohydrate recognition domain at 2.1 Å resolution. *J Biol Chem*. 1998; 273:13047–13052. [PubMed: 9582341]
12. Oda Y, Herrmann J, Gitt M, Turck C, Burlingame A, Barondes S, Leffler H. Soluble lactose-binding lectin from rat intestine with two different carbohydrate-binding domains in the same peptide chain. *J Biol Chem*. 1993; 268:5929–5939. [PubMed: 8449956]
13. Lobsanov YEA. X-ray crystal structure of the human dimeric S-Lac lectin, L-14-II, in complex with lactose at 2.9 Å resolution. *J Biol Chem*. 1993; 268:27034–27038. [PubMed: 8262940]
14. Bianchet M, Ahmed H, Vasta G, Amzel LM. Soluble  $\beta$ -galactosyl-binding lectin (galectin) from toad ovary: crystallographic studies of two protein-sugar complexes. *Proteins*. 2000; 40:378–388. [PubMed: 10861929]
15. Liao D, Kapadia G, Ahmed H, Vasta G, Herzberg O. Structure of S-lectin, a developmentally regulated vertebrate  $\beta$ -galactoside-binding protein. *Proc Natl Acad Sci USA*. 1994; 91:1428–1432. [PubMed: 8108426]
16. Hirabayashi J, Kasai K. Effect of amino acid substitution by site-directed mutagenesis on the carbohydrate recognition and stability of human 14-kDa  $\beta$ -galactoside-binding lectin. *J Biol Chem*. 1991; 266:23648–23653. [PubMed: 1721052]
17. Hirabayashi J, Kasai K-i. Further evidence by site-directed mutagenesis that conserved hydrophilic residues form a carbohydrate-binding of galectin-1. *Glycoconjugate J*. 1994; 11:437–442.
18. Rini J. X-ray crystal structures of animal lectins. *Curr Opin Struct Biol*. 1995; 5:617–621. [PubMed: 8574697]
19. Ahmed H, Allen HJ, Sharma A, Matta KL. Human splenic galaptin: carbohydrate-binding specificity and characterization of the combining site. *Biochemistry*. 1990; 29:5315–5319. [PubMed: 1696497]
20. Gupta D, Cho M, Cummings RD, Brewer CF. Thermodynamics of carbohydrate binding to galectin-1 from chinese hamster ovary cells and two mutants. A comparison with four galactose-specific plant lectins. *Biochemistry*. 1996; 48:15236–15243. [PubMed: 8952472]
21. Solomon J, Stoll M, Penfold P, Abbott W, Childs R, Hanfland P, Feizi T. Studies of the binding specificity of the soluble 14,000-dalton bovine heart muscle lectin using immobilized glycolipids and neoglycolipids. *Carbohydrate Res*. 1991; 213:293–307.
22. Schwarz F, Ahmed H, Bianchet M, Amzel LM, Vasta G. Thermodynamics of bovine spleen galectin-1 binding to disaccharides: correlation with structure and its effects of oligomerization at the denaturation temperature. *Biochemistry*. 1998; 37:5867–5877. [PubMed: 9558320]

23. Zhou Q, Cummings RD. L-14 lectin recognition of laminin and its promotion of *in vitro* cell adhesion. *Arch Biochem Biophys.* 1993; 300:6–17. [PubMed: 8380972]
24. Merkle R, Cummings R. Asparagine-linked oligosaccharides containing poly-*N*-acetylglucosamine chains are preferentially bound by immobilized calf heart agglutinin. *J Biol Chem.* 1988; 263:16143–16149. [PubMed: 3182789]
25. Woods RJ, Dwek RA, Edge CJ. Molecular mechanical and molecular dynamical simulations of glycoproteins and oligosaccharides. 1. GLYCAM\_93 parameter development. *J Phys Chem.* 1995; 99:3832–3846.
26. Tempel W, Tschampel S, Woods R. The xenograft antigen bound to *Griffonia simplicifolia* Lectin 1-B<sub>4</sub>. *J Biol Chem.* 2002; 277:6615–6621. [PubMed: 11714721]
27. Sayers EW, Prestegard JH. Conformation of a trimannoside bound to mannose-binding protein by nuclear magnetic resonance and molecular dynamics simulations. *Biophys J.* 2002; 82:2683–2699. [PubMed: 11964255]
28. Pathiaseril A, Woods RJ. Relative energies of binding for antibody-carbohydrate-antigen complexes computed from free-energy simulations. *J Am Chem Soc.* 2000; 122:331–338. [PubMed: 17211491]
29. Siebert H, von der Lieth C, Dong X, Reuter G, Schauer R, Gabius H, Vliegthart J. Molecular dynamics-derived conformation and intramolecular interaction analysis of the *N*-acetyl-9-*O*-acetyl-neuraminic acid-containing ganglioside GD1a and NMR-based analysis of its binding to a human polyclonal immunoglobulin G fraction with selectivity for *O*-acetylated sialic acids. *Glycobiol.* 1996; 6:561–572.
30. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The Protein Data Bank. *Nucleic Acids Res.* 2000; 28:235–242. [PubMed: 10592235]
31. Jorgensen W, Chandrasekhar J, Madura J, Impey R, Klein M. Comparison of simple potential functions for simulating liquid water. *J Chem Phys.* 1983; 79:926–935.
32. Case, DA.; Pearlman, DA.; Caldwell, JW.; Cheatham, TE.; Ross, WS.; Simmerling, CL.; Darden, TA.; Merz, KM.; Stanton, RV.; Cheng, AL.; Vincent, JJ.; Crowley, M.; Ferguson, DM.; Radmer, RJ.; Seibel, GL.; Singh, UC.; Weiner, PK.; Kollman, PA. AMBER 5.0. 1997.
33. Cornell WD, Cieplak P, Bayly CI, Gould IR, Merz KM, Ferguson DM, Spellmeyer DC, Fox T, Caldwell JW, Kollman PA. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. *J Am Chem Soc.* 1995; 117:5179–5197.
34. Woods RJ, Chappelle R. Restrained electrostatic potential atomic partial charges for condensed-phase simulations of carbohydrates. *J Mol Struct Theochem.* 2000; 527:149–156.
35. Essmann U, Perera L, Berkowitz M, Darden T, Lee H, Pedersen L. A smooth particle mesh Ewald method. *J Chem Phys.* 1995; 103:8577–8593.
36. Jayaram B, Sprous D, Beveridge D. Solvation free energy of macromolecules: Parameters for a modified generalized born model consistent with the AMBER force field. *J Phys Chem B.* 1998; 102:9571–9576.
37. Wolfe S, Rauk A, Tel LM, Csizmadia IG. A theoretical study of the Edward-Lemieux effect (the anomeric effect). The stereochemical requirements of adjacent electron pairs and polar bonds. *J Am Chem Soc.* 1971:136–145.
38. Weimar T. Manuscript in preparation.
39. Allen H, Ahmed H, Matta K. Binding of synthetic sulfated ligands by human splenic galectin-1, a  $\beta$ -galactoside-binding lectin. *Glyco-conjugate J.* 1998; 15:691–695.
40. Lemieux RU, Bock K, Delbaere LTJ, Koto S, Rao VS. The conformations of oligosaccharides related to the ABH and Lewis human blood group determinants. *Can J Chem.* 1980; 58:631–653.
41. Nagai K, Roberts D, Toida T, Matsumoto H, Kushi Y, Handa S, Ishizuka I. Mono-sulfated globopentaosylceramide from human kidney. *J Biol Chem.* 1989; 264:16229–16237. [PubMed: 2777788]
42. Roberts D, Ginsburg V. Sulfated glycolipids and cell adhesion. *Arch Biochem Biophys.* 1988; 267:405–415. [PubMed: 3063211]
43. Vyas NK. Atomic features of protein-carbohydrate interactions. *Curr Opin Struct Biol.* 1991; 1:732–740.

44. Jimenez-Barbero J, Asensio JL, Canada FJ, Poveda A. Free and protein-bound carbohydrate structures. *Curr Opin Struct Biol.* 1999; 9:549–555. [PubMed: 10508763]
45. Bush A, Martin-Pastor M, Imberty A. Structure and conformation of complex carbohydrates of glycoproteins, glycolipids, and bacterial polysaccharides. *Annu Rev Biophys Biomol Struct.* 1999; 28:269–293. [PubMed: 10410803]
46. Imberty A, Mikros E, Koca J, Mollicone R, Oriol R, Perez S. Computer simulation of Histo-blood group oligosaccharides: energy maps of all constituting disaccharides and potential energy surfaces of 14 ABH and Lewis carbohydrate antigens. *Glycoconjugate J.* 1995; 12:331–349.
47. Chong L, Duan Y, Wang L, Massova I, Kollman P. Molecular dynamics and free-energy calculations applied to affinity maturation in antibody 48G7. *Proc Natl Acad Sci USA.* 1999; 96:1433–14335. [PubMed: 9990041]
48. Srinivasan J, Cheatham TE, Cieplak P, Kollman P, Case D. Continuum solvent studies of the stability of DNA, RNA, and phosphoramidate-DNA helices. *J Am Chem Soc.* 1998; 120:9401–9409.
49. Tsui V, Case D. Theory and applications of the generalized born solvations model in macromolecular simulations. *Biopolymers.* 2001; 56:275–291. [PubMed: 11754341]
50. Tsui V, Case D. Calculations of the absolute free energies of binding between RNA and metal ions using molecular dynamics simulations and continuum electrostatics. *J Phys Chem.* 2001; 105:11314–11325.
51. Lazaridis T. Binding affinity and specificity from computational studies. *Current Organic Chemistry.* 2002; 6:1319–1332.
52. Archontis G, Simonson T, Karplus M. Binding free energies and free energy components from molecular dynamics and Poisson-Boltzmann calculations. Application to amino acid recognition by aspartyl-tRNA synthetase. *J Mol Biol.* 2001:306–327.
53. Baruffi M, Bochkareva E, Rogers K, Stowell S, Bochkarev A, Cummings R. Crystal structures of human galectin-1 with low molecular weight ligands at 1.6–1.9Å, and analysis of the ligand binding affinity to galectin-1 determined by isothermal titration calorimetry. *Glycobiology.* 2002; 12:Abstract 177.
54. Ledvina P, Yao N, Choudhary A, Quijcho F. Negative electrostatic surface potential of protein sites specific for anionic ligands. *Proc Natl Acad Sci USA.* 1996; 93:6786–6791. [PubMed: 8692896]
55. Imberty A, Delage M, Bourne Y, Cambillau C, Perez S. Data bank of three-dimensional structures of disaccharides: Part II, N-acetyllactosaminic type N-glycans. Comparison with the crystal structure of a biantennary octasaccharide. *Glycoconjugate J.* 1991; 8:456–483.




**Fig. 1.** X-ray structure of the galectin-1 complex with **1** (Liao et al.<sup>15</sup>). (a) Dimer structure showing the pseudo-symmetric dimer of galectin-1 (ribbon) with bound LacNAc (stick). (b) Galectin-1 monomer as employed in the MD simulations. Binding site residues allowed motional freedom during restrained simulations are depicted with red ribbon. (c) Detail of CRD showing conserved amino acids important in LacNAc binding.




**Fig. 2.** Modeled structures of galectin-1-ligand complexes with (a) **2**, (b) **4**, and (c) **5**.






**Fig. 3.** Diffusion of negative controls from the galectin-1 CRD. (a) Relative RMSD of the glycan center of mass. (b) Persistence of hydrogen bonds ( $r_{H-bond} < 4.0 \text{ \AA}$ ) during the diffusion of Glc-β-(1,4)-GlcNAc from the CRD.



**Fig. 4.** GRASP representation of the electrostatic potential of galectin-1 mapped onto the solvent accessible surface. Regions of positive potential are shown in blue, and negative potential is shown in red. The values set for the coloring scale are  $-3.6$  and  $+3.7$   $k_bT$ , respectively. LacNAc is shown in stick form. The sulfate, found at the nonreducing terminus, is shown in yellow.

**Scheme 1.**

Selected ligands of galectin-1. (1) Glu-71 O $\epsilon$ 2-GlcNAc-O3; (2) Arg-73 N $\eta$ 2-GlcNAc-O3; (3) Arg-48 N $\eta$ 1-GlcNAc-O5; (4) Arg-48 N $\eta$ 2-GlcNAc-O4; (5) Arg-48 N $\eta$ 2-GlcO5; (6) His-44 N $\epsilon$ -Glc-O4; (7) Asn-61 N $\delta$ 2-Glc-O6.

TABLE I

Relative Affinities of Galectin-1 Ligands<sup>†</sup>

Ligand	$K_a^a$ SPR <sup>38</sup>	$K_a^b$ ITC <sup>22</sup>	Activity <sup>c</sup> ELISA <sup>39</sup>
Lactose (Gal- $\beta$ -(1,4)-Glc)	1.0	1.0	1.0
<b>1</b> LacNAc <sub>II</sub> (Gal- $\beta$ -(1,4)-GlcNAc)	2.4	5.5	5.5
<b>2</b> LacNAc <sub>I</sub> (Gal- $\beta$ -(1,4)-GlcNAc)	2.4	5.5	5.5
<b>3</b> 3'-SO <sub>3</sub> -Gal- $\beta$ -(1,4)-GlcNAc		4.0	
<b>4</b> Neu5Ac- $\alpha$ -(2,3)-Gal- $\beta$ -(1,4)-GlcNAc	3.3		
<b>5</b> (LacNAc) <sub>2</sub> (Gal- $\beta$ -(1,4)-GlcNAc- $\beta$ -(1,3)-Gal- $\beta$ -(1,4)-GlcNAc)			
<b>6</b> GlcNAc			
<b>7</b> Glc- $\beta$ -(1,4)-GlcNAc			

<sup>†</sup> Affinities are relative to Gal- $\beta$ -(1,4)-Glc- $\beta$ -OR. For SPR studies, sugar is linked to Biacore chip via spacer, which is  $\beta$ -linked to the reducing termini of sugar ligands; other studies use the free saccharide.

<sup>a</sup> Chinese hamster galectin-1 (C2S mutant).

<sup>b</sup> Bovine spleen galectin-1.

<sup>c</sup> Alkylated human galectin-1.

Hydrogen Bond Distances, Ligand RMS Values, and Simulation Parameters for Three Treatments of Solvation and Electrostatics for the Complex with 1<sup>†</sup>

TABLE II

Residue	Protein atom	Carbohydrate atom	X-ray <sup>a</sup>	Droplet	PBC	PBC PME
His-44	Ne	Gal-O4	2.8	3.0 (0.2) <sup>b</sup>	3.0 (0.2)	3.4 (0.4)
Asn-46	Oδ1	Gal-O4	3.4	3.4 (0.3)	3.4 (0.3)	3.4 (0.3)
Arg-48	Nη2	Gal-O4	3.0	2.9 (0.2)	2.9 (0.2)	3.0 (0.2)
Arg-48	Nη2	Gal-O4	3.0	2.9 (0.2)	2.9 (0.1)	3.0 (0.2)
Asn-61	Nδ2	Gal-O6	2.7	3.0 (0.2)	2.9 (0.1)	3.0 (0.2)
Glu-71	Oε1	Gal-O6	4.7	4.3 (0.6)	3.8 (0.9)	4.6 (0.2)
Glu-71	Oε2	Gal-O6	2.8	2.9 (0.6)	3.5 (0.9)	2.7 (0.1)
Arg-48	Nη1	GlcNAc-O3	2.8	2.9 (0.1)	2.9 (0.1)	2.8 (0.1)
Arg-48	Nη2	GlcNAc-O3	3.2	3.3 (0.3)	3.4 (0.3)	3.3 (0.2)
Arg-48	Nη1	GlcNAc-O4	4.2	4.1 (0.3)	4.1 (0.3)	4.3 (0.3)
Arg-48	Nη2	GlcNAc-O4	3.6	3.6 (0.3)	3.5 (0.2)	3.5 (0.3)
Glu-71	Oε1	GlcNAc-N	4.0	3.8 (0.5)	4.0 (0.6)	3.5 (0.2)
Glu-71	Oε1	GlcNAc-O3	3.3	2.9 (0.3)	2.9 (0.4)	3.0 (0.2)
Glu-71	Oε2	GlcNAc-O3	2.4	3.2 (0.5)	3.0 (0.4)	2.8 (0.2)
Arg-73	Nη1	GlcNAc-C=O	4.5	4.1 (0.6)	4.3 (0.5)	4.5 (0.6)
Arg-73	Nη2	GlcNAc-C=O	3.3	4.5 (0.4)	4.5 (0.4)	4.6 (0.4)
Arg-73	Nη1	GlcNAc-O3	4.7	4.1 (0.5)	4.5 (0.4)	4.6 (0.4)
Arg-73	Nη2	GlcNAc-O3	3.3	3.1 (0.3)	3.3 (0.3)	3.4 (0.4)
Binding site RMSD						
All atoms						
Backbone only						
LacNAc ring atoms only						
No. of particles				7278	16056	16056
Simulation time (h)				168	436	604

<sup>†</sup> Distances are in Ångstroms, and root-mean-squared deviation (Å) in the nonhydrogen atomic positions, relative to the X-ray structure.

<sup>a</sup> Liao et al.<sup>15</sup>

<sup>b</sup> Standard deviations in parentheses.

TABLE III

Ligand-Galectin-1 Heavy Atom Distances and Ligand RMS Values as a Function of Simulation Protocol for 2 ns Simulations

Residue	Protein atom	Carbohydrate atom	1 (X-ray <sup>a</sup> )	Ligand				
				2	3	4	5	
His-44	Nε	Gal-O4	2.8	3.2 (0.5)	3.0 (0.2)	3.1 (0.2)	2.9 (0.1)	
Asn-46	Oδ1	Gal-O4	3.4	3.9 (1.0)	3.7 (0.5)	3.3 (0.2)	3.5 (0.2)	
Arg-48	Nη2	Gal-O4	3.0	3.8 (1.1)	3.2 (0.4)	2.9 (0.1)	2.9 (0.1)	
Arg-48	Nη2	Gal-O5	2.9	3.5 (0.8)	3.0 (0.2)	2.9 (0.1)	3.1 (0.2)	
Asn-61	Nδ2	Gal-O6	2.7	3.0 (0.2)	3.0 (0.2)	2.9 (0.1)	3.0 (0.1)	
Glu-71	Oε1	Gal-O6	4.7	5.3 (1.4)	3.9 (0.8)	4.8 (0.2)	5.3 (0.1)	
Glu-71	Oε2	Gal-O6	2.8	5.1 (0.8)	4.3 (0.7)	2.9 (0.1)	2.8 (0.1)	
Arg-48	Nη1	GlcNAc-O3	2.8	4.1 (1.2)	3.0 (0.2)	3.7 (0.2)	3.1 (0.1)	
Arg-48	Nη2	GlcNAc-O3	3.2	3.8 (0.8)	3.5 (0.3)	5.0 (0.2)	4.5 (0.2)	
Arg-48	Nη1	GlcNAc-O4	4.2	3.6 (0.6)	3.9 (0.3)	3.7 (0.2)	3.6 (0.2)	
Arg-48	Nη2	GlcNAc-O4	3.6	3.2 (0.4)	3.5 (0.3)	3.4 (0.2)	3.3 (0.2)	
Glu-71	Oε1	GlcNAc-N	4.0	—	4.0 (0.5)	2.9 (0.2)	3.0 (0.1)	
Glu-71	Oε1	GlcNAc-O3	3.3	—	2.9 (0.5)	2.7 (0.1)	2.7 (0.1)	
Glu-71	Oε2	GlcNAc-O3	2.4	—	3.9 (0.7)	5.1 (0.6)	6.6 (0.2)	
Arg-73	Nη1	GlcNAc-C=O	4.5	—	4.0 (0.5)	4.7 (0.4)	7.7 (0.2)	
Arg-73	Nη2	GlcNAc-C=O	3.3	—	4.4 (0.4)	4.5 (0.3)	2.8 (0.1)	
Arg-73	Nη1	GlcNAc-O3	4.7	—	3.7 (0.3)	3.3 (0.3)	3.1 (0.1)	
Arg-73	Nη2	GlcNAc-O3	3.3	—	3.0 (0.1)	2.9 (0.1)	2.8 (0.1)	
RMSD								
	CRD All atoms			1.2 (0.2)	1.2 (0.5)	1.4 (0.3)	0.8 (0.1)	
	CRD Backbone			0.9 (0.2)	0.7 (0.3)	0.9 (0.3)	0.5 (0.1)	
	LacNAc ring atoms			1.5 (0.5)	1.4 (1.2)	1.4 (0.4)	1.2 (0.5)	

<sup>a</sup>Liao et al.<sup>15</sup>

**TABLE IV**

Predicted Hydrogen Bond Distances between Extended Ligands and the Galectin-1 CRD

Ligand	Carbohydrate atom	CRD residue	Protein atom	Distance
<b>4</b>	Neu5Ac-O9	Asn-33	N82	4.7 (1.4)
	Neu5Ac-O1A <sup>a</sup>	His-52	Ne	4.4 (0.5)
	Neu5Ac-O1B	His-52	Ne	3.1 (0.5)
	Neu5Ac-O7	Trp-68	Ne1	3.3 (0.4)
<b>5</b>	Gal <sub>2</sub> -O3 <sup>b</sup>	Asp-38	O82	3.8 (0.8)


<sup>a</sup>O1A and O1B are the carboxylate oxygens in Neu5Ac, with O1A being more deeply buried in the protein binding site.

<sup>b</sup>Gal<sub>2</sub> is the galactose of the non-core LacNAc in **5**.

TABLE V

Ring Stacking between Trp-68 and the Galactose Ring of Core LacNAc

X-ray	1	2	3	4	5	
$\theta^a$	142	131.0 (10.0)	133.2 (21.8)	131.7 (10.3)	144.0 (3.8)	157.8 (4.0)
$R^b$	5.1	6.0 (0.3)	5.6 (.9)	5.4 (0.4)	5.8 (0.2)	5.5 (0.1)



<sup>a</sup>The angle is degrees between the surface normals to the plane of the ring of Trp-68 and galactose. For a perfectly planar system the angle would be 180°. Standard deviations shown in parentheses.

<sup>b</sup>Distance in Ångstroms between the geometric centroids.



**TABLE VI**

Average Glycosidic Torsion Angles for Ligands in the Protein-bound and Free States

Ligand	Linkage	Torsion angle		
		Bound	Free	
<b>1</b>	$\beta$ -(1,4) <sub>1</sub>	$\phi^a$	45.9 (9.3)	46.6 (11.2)
		$\psi$	15.7 (8.5)	0.6 (12.8)
<b>3</b>	$\beta$ -(1,4) <sub>1</sub>	$\phi$	38.9 (11.4)	47.7 (11.8)
		$\psi$	17.6 (9.7)	-6.2 (13.2)
<b>4</b>	$\alpha$ -(2,3) <sub>2</sub>	$\phi^b$	158.8 (12.9)	-169.7 (12.4)
		$\psi$	8.1 (11.5)	-13.8 (11.9)
	$\beta$ -(1,4) <sub>1</sub>	$\phi$	45.1 (10.3)	45.1 (11.9)
		$\psi$	14.2 (9.5)	-6.3 (12.5)
<b>5</b>	$\beta$ -(1,4) <sub>3</sub>	$\phi$	51.1 (11.9)	40.8 (14.7)
		$\psi$	13.1 (15.3)	-5.4 (15.7)
	$\beta$ -(1,3) <sub>2</sub>	$\phi$	68.6 (14.9)	41.7 (13.8)
		$\psi$	29.2 (19.1)	11.8 (45.2)
	$\beta$ -(1,4) <sub>1</sub>	$\phi$	55.0 (9.0)	46.9 (12.1)
$\psi$	4.0 (7.8)	-3.3 (12.3)		

<sup>a</sup>  $\phi$  and  $\psi$  values for  $\beta$ -(1,3) and (1,4) linkages defined as: H1-C1-Ox-Cx and C1-Ox-Cx-Hx, respectively.

<sup>b</sup>  $\phi$  and  $\psi$  values for  $\alpha$ -(2,3) linkage defined as C1-C2-O3-C3 and C2-O3-C3-H3, respectively.

TABLE VII

Energy Component Analysis of MD Trajectories<sup>†</sup>

	1	2	3	4	5
$\langle E_{elec} \rangle$	-67.5 (5.7)	-30.8 (11.2)	-59.9 (9.7)	-53.2 (8.3)	-103.0 (15.0)
$\langle E_{vdw} \rangle$	-17.5 (3.8)	-17.0 (3.4)	-23.9 (3.2)	-24.4 (3.6)	-37.9 (4.1)
$\langle E_{MM} \rangle$	-84.9 (5.9)	-47.9 (12.7)	-83.8 (9.5)	-77.6 (9.7)	-141.0 (15.4)
$\langle G_{np} \rangle$	-3.7 (0.3)	-2.7 (0.7)	-4.2 (0.2)	-4.7 (0.3)	-6.4 (0.5)
$\langle G_{pol} \rangle$	15.4 (4.4)	6.5 (8.5)	1.2 (6.8)	6.0 (10.3)	23.9 (12.5)
$\langle G_{olv} \rangle$	11.7 (4.5)	3.8 (8.7)	-3.0 (6.8)	1.4 (10.2)	17.5 (12.4)
$\langle G_{elec,tot} \rangle$	-52.2 (6.9)	-24.3 (12.7)	-58.7 (8.3)	-47.1 (10.7)	-79.1 (13.7)
$\langle G_{tot} \rangle$	-73.3 (7.3)	-44.1 (14.9)	-86.7 (7.8)	-76.2 (11.8)	-123.5 (13.8)
$\langle -T S \rangle$	18.3 (3.7)	18.2 (4.0)	22.5 (4.3)	30.1 (5.4)	31.6 (2.5)
$G_{binding}$					
$(\epsilon_{int} = 1)^{\ddagger\ddagger}$	-55.0 (8.3)	-25.9 (7.2)	-64.2 (9.0)	-46.1 (7.7)	-91.9 (8.8)
$(\epsilon_{int} = 4)$	-16.0 (2.6)	-7.7 (1.7)	-20.2 (2.7)	-11.0 (1.6)	-32.8 (2.6)

<sup>†</sup>Values are expressed in kcal/mol, with standard deviations in parentheses.

$\langle E_{elec} \rangle$ , electrostatic molecular mechanical energy;  $\langle E_{vdw} \rangle$ , van der Waals molecular mechanical energy;  $\langle E_{MM} \rangle = \langle E_{elec} \rangle + \langle E_{vdw} \rangle$ , total molecular mechanical energy;  $\langle G_{np} \rangle$ , non-polar contribution to the solvation energy;  $\langle G_{pol} \rangle$ , polar contribution to the solvation energy;  $\langle G_{olv} \rangle = \langle G_{np} \rangle + \langle G_{pol} \rangle$ , total solvation energy;  $\langle G_{elec,tot} \rangle = \langle E_{elec} \rangle + \langle G_{pol} \rangle$ , total electrostatic energy;  $\langle G_{tot} \rangle$ , total energy (without entropic contribution);  $\langle -T S \rangle = -T S$  (sum of rotational, translational and vibrational entropies);  $G_{binding}$ , total binding energy of the system.

<sup>‡‡</sup> $\langle E_{elec} \rangle$  and  $\langle G_{pol} \rangle$  respond inversely to the dielectric constant.